Investor Announcements - 2018
Annual Report and Accounts for the year ended 31 December 2017 now available.
EKF announces US Food and Drug Administration 510(k) clearance and CLIA waiver for DiaSpect Tm.
Notification of major holdings.
EKF Diagnostics announces its final results for the year ended 31 December 2017.
EKF Diagnostics announces that it will release its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.
EKF Diagnostics provides shareholders with the following update on current trading.